• IRLAB Therapeutics plans to cut approximately 10 positions, or 30% of its workforce, primarily in early-stage research and development.
• The proposed reductions remain subject to consultations with employee representatives before a final decision.
• The strategic changes are expected to reduce annual costs by approximately SEK 8 million, with significant savings from Q3 2027.
• Resources will shift toward revenue-generating partnerships for the existing drug portfolio, reducing investment in discovering new drug candidates.
• A reduced likelihood of securing new partnership agreements in 2026 has increased the need for strict cost control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.